CMSC

Defining what advanced disease means in multiple sclerosis is a topic open for discussion. Deciding a course of treatment after that determination is another challenge in overall patient care.

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help manage their symptoms.

While it may not be possible to compare the efficacy of treatments for multiple sclerosis in clinical trials work is being done to look at the various options through results in actual practice.

Research into the inner workings of multiple sclerosis comes in all shapes and sizes including looking at specific parts of the brain. A recent study has looked at the role of the blood brain barrier and how it affects patients with this condition.

There are conferences held all over the world working to improve treatment of multiple sclerosis. The consortium of Multiple Sclerosis Centers is one that takes a different approach to this condition.

Individual trials have shown various benefits associated with fingolimod (Gilenya) for relapsing-remitted multiple sclerosis (RRMS), but its consistency across studies has not been fully understood.

Fingolimod (Gilenya) is an immunosuppressant used to treat multiple sclerosis, but improvements with disability have been unsteady with this drug.

Country music artist, Clay Walker – who is well-known for his hit songs “She Won’t Be Lonely Long†and “Live Until I Die" – was diagnosed with a relapsing form of multiple sclerosis (MS) at the age of 26.

“Disabled people aren’t sexually attractive†is just one real quote – and myth – from someone living with multiple sclerosis.

While newly approved treatments for multiple sclerosis move away from interferon based medications Rebif continues to be a popular choice after more than a decade in the field.

The treatment of multiple sclerosis requires the work of more than just neurologists and that figures to be the case well into the future as well.

Throughout medicine personalized care is becoming an increasing focus of the field. This is no exception for the treatment of multiple sclerosis where patients may find a medication which works for a short time before needing to find a new option.

Marijuana and alcohol – studies suggest that one of these substances helps patients with multiple sclerosis while the other can contribute to comorbidities.

Lifestyle factors and multiple sclerosis is a two-way street; but what does that mean for practicing physicians? Allen Bowling, MD, PhD, explains at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.

Perfecting an exercise regimen on an individual basis for people with multiple sclerosis is no easy task, as described at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.

A change in appetite may not be a huge red flag in most people, but in patients with multiple sclerosis, it could have a larger meaning.

To date, there is no treatment approved by the US Food and Drug Administration (FDA) for primary progressive multiple sclerosis. But a promising treatment could change that regardless of apparent skin reactions.

Disease-modifying therapies (DMTs) help reduce relapses in people with multiple sclerosis. While options have expanded, little is known about which one has the greatest effectiveness.

A phase III study that examined teriflunomide (Aubagio) in a subtype of patients with multiple sclerosis was presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.

There are various disease-modifying treatment (DMT) options for patients with relapsing-remitting multiple sclerosis (RRMS). But how much do neurologists and patients agree on the first-line course?

With research of progressive multiple sclerosis lagging behind that of the relapsing form of the condition a group of the top minds from around the world is looking to speed up the process to help patients that need it most.

It was a busy few days in Indianapolis for the Consortium of Multiple Sclerosis Centers. The annual meeting highlighted not only new treatments currently available to patients but also work coming down the pipeline for future options.

The development of new monoclonal antibodies could provide benefit for patients with multiple sclerosis in the future. Exactly how they will be used and what their usage could mean for treatment remains to be determined.

There are many things patients with multiple sclerosis can do to help in their own treatment of the condition. Research is looking at how diet can help improve quality of life and make a difference in the bigger picture.

One of the scariest things a patient with multiple sclerosis can experience is a relapse of their symptoms, particularly after a period of calm. How they are treated can determine their quality of life going forward.

When it comes to stretching and exercise one of the most common options for many people is yoga. While there are some considerations to work with, some studies have shown it can also be beneficial for patients with multiple sclerosis.

Treatment of the relapsing form of multiple sclerosis has come a long way in recent years. The hope by researchers now is that treatment for progressive multiple sclerosis could be coming up sooner rather than later.

A growing trend in the medical community is the use of a technique known as mindfulness based stress reduction. While the results have shown to be inconclusive in the treatment of multiple sclerosis there is work being done to show its efficacy in helping patients.

Patients with multiple sclerosis face stress from a variety of sources. How they address that stress can make a significant difference in their overall quality of life.

When looking at ways to help patients with multiple sclerosis, one alternative method to use could be progressive muscle relaxation.